Literatur
- 1 Altenhofen L. Hochrechnung zur Akzeptanz von Gesundheitsuntersuchungen und Krebsfrüherkennungsuntersuchungen
bei gesetzlich Versicherten. Zentralinstitut für die kassenärztliche Versorgung in
der Bundesrepublik Deutschland Berlin 2005
- 2
Baseman J G, Koutsky L A.
The epidemiology of human papillomavirus infections.
J Clin Virol.
2005;
32
S16-24
- 3 Bertz J, Giersiepen K, Haberland J. et al .Krebs in Deutschland. 5. überarbeitete,
aktualisierte Ausgabe. Gesellschaft der epidemiologischen Krebsregister in Deutschland
e. V. und das RKI Saarbrücken 2006
- 4
Block S L, Nolan T, Sattler C. et al .
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent
human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male
and female adolescents and young adult women.
Pediatrics.
2006;
118
2135-2145
- 5
Bryan J T, Smith J F, Ruiz W, Brownlow M K, Brown M J, Esser M T.
Evaluation of antibodies induced by an HPV vaccine to cross-neutralize pseudovirions
fo vaccine-related HPV types.
J Clin Oncol ASCO Annual Meeting Proceedings Part I.
2006;
24
(18S)
15008
- 6
Carter J J, Koutsky L A, Hughes J P. et al .
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following
incident infection.
J Infect Dis.
2000;
181
(6)
1911-9
- 7
Castellsague X, Diaz M, de Sanjose S. et al .
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors:
implications for screening and prevention.
J Natl Cancer Inst.
2006;
98
303-15
- 8
Clifford G M, Smith J S, Plummer M, Munoz N, Franceschi S.
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.
Br J Cancer.
2003;
88
(1)
63-73
- 9
Durst M, Gissmann L, Ikenberg H, zur Hausen H.
A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy
samples from different geographic regions.
Proc Natl Acad Sci USA.
1983;
80
3812-5
- 10 Fachinformation Gardasil. Merck C., inc., Whitehouse station, NJ 08889, U.S.A. 2006
- 11
FUTURE II Study Group .
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
N Engl J Med.
2007;
356
(19)
1915-27
- 12
Garland S M, Hernandez-Avila M, Wheeler C M. et al, for the Females United to Unilaterally
Reduce Endo/Ectocervical Disease (FUTURE) I Investigators .
Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases.
N Engl J Med.
2007;
356
1928-43
- 13
Gieseking F, Petry K U, Hillemanns P, Germé M, Littlewood K J, Bénard S, Breugelmanns J G.
Incidence, prevalence and costs of treating genital warts in the pre-HPV vaccine era
in Germany, 2005.
Value in Health.
2005;
8
(6)
A64-65
- 14
Gissmann L, Wolnik L, Ikenberg H, Koldovsky U, Schnurch H G, zur Hausen H.
Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas
and in some cervical cancers.
Proc Natl Acad Sci U S A.
1983;
80
(2)
560-3
- 15
Gross G.
Für das Deutsche HPV-Management-Forum Wer sollte wann, wo und wie geimpft werden?.
Dtsch Ärzteblatt.
2006;
103
(50)
3384-3388
- 16
Harper D M, Franco E L, Wheeler C. et al .
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with
human papillomavirus types 16 and 18 in young women.
Lancet.
2004;
364
1757-65
- 17
Harper D M, Franco E L, Wheeler C M. et al .
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against
human papillomavirus types 16 and 18.
Lancet.
2006;
367
1247-55
- 18
Munoz N, Bosch F X, de Sanjose S. et al .
Epidemiologic classification of human papillomavirus types associated with cervical
cancer.
N Engl J Med.
2003;
348
518-27
- 19
Parkin D M, Bray F, Ferlay J, Pisani P.
Global cancer statistics, 2002.
CA Cancer J Clin.
2005;
55
74-108
- 20
Peto J, Gilham C, Fletcher O, Matthews F E.
The cervical cancer epidemic that screening has prevented in the UK.
Lancet.
2004;
364
(9430)
249-56
- 21
Petry K U, Hillemanns P, Germé M, Littlewood K J, Bérnard S, Breugelmans J G.
Resource use and costs associated with the managementof PAP III, PAP IIID and PAP
IV in the pre-HPV vaccine era in Germany.
Value in Health.
2005;
8
(6)
A64
- 22 Robert Koch Institut .Dachdokumentation Krebs, www.rki.de . Abfrage: 03.01.2006.
- 23
Robert Koch Institut .
Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Impfung gegen
humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren - Empfehlung und Begründung.
Epidemiol Bull.
2007;
12
97-103
- 24
Smith H O, Tiffany M F, Qualls C R, Key C R.
The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the
uterine cervix in the United States.
Gynecol Oncol.
2000;
78
97-105
- 25 Statistisches Bundesamt .Krankheitskosten 2002. Statistisches Bundesamt Wiesbaden
2004
- 26 Statistisches Bundesamt .Gesundheitsberichterstattung, Todesursachenstatistik,
www.gbe-bund.de, Abfrage: 03.01.2006.
- 27
Taira A V, Neukermans C P, Sanders G D.
Evaluating human papillomavirus vaccination programs.
Emerg Infect Dis.
2004;
10
(11)
1915-23
- 28
Villa L L, Costa R L, Petta C A. et al .
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like
particle vaccine in young women.
Lancet Oncol.
2005;
6
271-8
- 29
Villa L L, Costa R L, Petta C A. et al .
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types
6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.
Br J Cancer.
2006a;
95
(11)
1459-66
- 30
Villa L L, Ault K A, Giuliano A R. et al .
Immunologic responses following administration of a vaccine targeting human papillomavirus
types 6, 11, 16, and 18.
Vaccine.
2006b;
24
(27-28)
5571-83
- 31
Viscidi R P, Schiffman M, Hildesheim A. et al .
Seroreacitivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent
HPV infection: results from a population-based study in Costa Rica.
Cancer Epidemiol Biomarkers Prev.
2004;
13
324-327
- 32
Walboomers J M, Jacobs M V, Manos M M. et al .
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
J Pathol.
1999;
189
12
- 33
zur Hausen H.
Papillomaviruses and cancer: from basic studies to clinical application.
Nat Rev Cancer.
2002;
2
(5)
342-50
- 34
Schneider A, Schwarz T F, Hammerschmidt T, Siebert U.
Einfluss einer Impfung gegen humane Papillomviren auf die Inzidenz und Mortalität
von Zervixkarzinom in Deutschland.
Med Klin.
2007;
102 (7)
515-523
Prof. Dr. med. Achim Schneider, M. P. H.
Klinik für Gynäkologie, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
Hindenburgdamm 30
12200 Berlin
Phone: 030/8445-2591
Fax: 030/8445-4477
Email: achim.schneider@charite.de
